Dana D. Hu‐Lowe

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.2K citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +12

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

Michael R. Mancuso, Rachel Davis, Scott M. Norberg et al. · Journal of Clinical Investigation · 2006 · 798 citations · Full text

Medicine, Oncology, Pharmacology +14

Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts

Tetsuichiro Inai, Michael R. Mancuso, Hiroya Hashizume et al. · American Journal Of Pathology · 2004 · 763 citations · Full text

Medicine, Cancer Biology, Oncology +17

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

Medicine, Oncology, Pharmacology +17

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling

Fabienne Baffert, Tom Le, Barbara Sennino et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2005 · 371 citations

Life Sciences, Cell Biology, Molecular Biology +14